Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 74065P101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
16.0% |
4/23/2026
Event 4/21/2026
|
||
| Orbimed Advisors LLC | 16.0% | |||
| Orbimed Capital GP VI LLC | 14.6% | |||
| OrbiMed Genesis GP LLC | 1.4% | |||
| Orbimed Capital LLC | 1.0% | |||
|
Baker Bros. Advisors LP
13D/A
|
15.5% |
4/22/2026
Event 4/20/2026
|
||
| Baker Bros. Advisors LP | 15.5% | |||
| Baker Bros. Advisors (GP) LLC | 15.5% | |||
| Julian C. Baker | 15.5% | |||
| Felix J. Baker | 15.5% | |||
| Vaddi Krishna 13G/A | 13.2% |
2/13/2026
Event 12/31/2025
|
||
|
RA Capital Management, L.P.
13G
|
9.9% |
4/28/2026
Event 4/21/2026
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
| Incyte Corp 13G | 9.9% |
11/7/2025
Event 11/3/2025
|
||
|
Soleus Private Equity Fund III, L.P.
13G
|
5.2% |
7/8/2026
Event 4/21/2026
|
||
| Soleus Private Equity Fund III, L.P. | 1.0% | |||
| Soleus Private Equity GP III, LLC | 1.0% | |||
| Soleus PE GP III, LLC | 1.0% | |||
| Soleus Capital Master Fund, L.P. | 4.2% | |||
| Soleus Capital, LLC | 4.2% | |||
| Soleus Capital Group, LLC | 4.2% | |||
| Soleus Capital Management, L.P. | 5.2% | |||
| Soleus GP, LLC | 5.2% | |||
| Levy Guy | 5.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
|
James E. Flynn
13G/A
|
0% |
2/13/2025
Event 12/31/2024
|
||
| Deerfield Mgmt, L.P. | 0% | |||
| Deerfield Management Company, L.P. | 0% | |||
| Deerfield Partners, L.P. | 0% | |||
| James E. Flynn | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 539 | $2.11 k |
| 2026 Q2 | 81 | 49.6 M | $264 M |
| 2026 Q1 | 56 | 30.8 M | $105 M |
| 2025 Q4 | 50 | 28.5 M | $82.6 M |
| 2025 Q3 | 48 | 27.2 M | $39.1 M |
| 2025 Q2 | 52 | 27.2 M | $22.0 M |
| 2025 Q1 | 61 | 30.5 M | $26.9 M |
| 2024 Q4 | 64 | 32.2 M | $41.0 M |
| 2024 Q3 | 74 | 35.8 M | $74.0 M |
| 2024 Q2 | 66 | 34.2 M | $130 M |
| 2024 Q1 | 63 | 34.8 M | $165 M |
| 2023 Q4 | 62 | 35.1 M | $150 M |
| 2023 Q3 | 63 | 36.6 M | $113 M |
| 2023 Q2 | 58 | 38.5 M | $176 M |
| 2023 Q1 | 57 | 31.5 M | $180 M |
| 2022 Q4 | 64 | 31.2 M | $189 M |
| 2022 Q3 | 56 | 31.8 M | $210 M |
| 2022 Q2 | 65 | 32.7 M | $171 M |
| 2022 Q1 | 72 | 34.1 M | $236 M |
| 2021 Q4 | 80 | 35.2 M | $438 M |
| 2021 Q3 | 62 | 36.0 M | $1.12 B |
| 2021 Q2 | 59 | 34.5 M | $987 M |
| 2021 Q1 | 61 | 32.5 M | $1.41 B |
| 2020 Q4 | 52 | 34.7 M | $2.47 B |
| 2020 Q3 | 41 | 33.3 M | $1.00 B |